Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

BACKGROUND: Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor which is used for non-small-cell lung cancer treatment. Despite that erlotinib is considered to have a favorable safety profile, adverse events such as interstitial lung disease (ILD) were repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Makris, Demosthenes, Scherpereel, Arnaud, Copin, Marie Christine, Colin, Guillaume, Brun, Luc, Lafitte, Jean Jacques, Marquette, Charles Hugo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1963454/
https://www.ncbi.nlm.nih.gov/pubmed/17683587
http://dx.doi.org/10.1186/1471-2407-7-150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1963454/
https://www.ncbi.nlm.nih.gov/pubmed/17683587
http://dx.doi.org/10.1186/1471-2407-7-150

Ejemplares similares